PIERRE, S.D. – South Dakota is set to receive more than $1.5 million as part of a $720 million national settlement with eight opioid manufacturers, according to Attorney General Marty Jackley. The money will go into the state’s National Opioid Settlement Fund, which is administered by the South Dakota Department of Social Services.
“No amount of money will ever be enough to compensate South Dakota families who have suffered because of the involvement of these companies in the opioid drug crisis,” said Jackley. “Now is the time to use these funds to help others in the areas of addiction treatment, prevention, and recovery.”
The settlement is part of an estimated $79 million South Dakota expects to receive through multiple agreements with pharmaceutical companies accused of fueling the opioid epidemic.
The eight latest companies and their contributions are as follows:
· Mylan (now part of Viatris): $284,447,916 paid over nine years
· Hikma: $95,818,293 paid over one to four years
· Amneal: $71,751,010 paid over 10 years
· Apotex: $63,682,369 paid in a single year
· Indivior: $38,022,450 paid over four years
· Sun: $30,992,087 paid over one to four years
· Alvogen: $18,680,162 paid in a single year
· Zydus: $14,859,220 paid in a single year
This latest settlement comes after a separate $7.4 billion national settlement involving Purdue Pharma and the Sackler family. South Dakota is expected to receive approximately $10.1 million from that deal, distributed over 15 years.
